<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986817</url>
  </required_header>
  <id_info>
    <org_study_id>P071215</org_study_id>
    <nct_id>NCT00986817</nct_id>
  </id_info>
  <brief_title>Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin</brief_title>
  <acronym>TERAS</acronym>
  <official_title>Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ascites is a common complication of cirrhosis. Sodium restriction and diuretics are the first
      step treatment. Refractory ascites (not responding to first step treatment) is treated with
      repeated large volume paracentesis followed by intra venous albumin expansion. In pilot
      studies vasoconstrictor agents such as terlipressin have shown beneficial effect on ascites
      production. Therefore the investigators will study the effect of combined therapy with
      albumin and terlipressin on recidivation ascites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 30% of cirrhotic patients will develop ascites. Sodium restriction and diuretics are
      the first step treatment. Total paracentesis is used in patients with cirrhosis and tense
      ascites. Paracentesis alone was found to induce a decrease in effective arterial blood
      volume. This circulatory dysfunction may induce inhospital complications such as impaired
      renal function or hyponatremia and is associated with a significant reduction in long term
      survival. Intravenous albumin administration after paracentesis has been shown to prevent the
      post paracentesis decrease in arterial blood volume. Paracentesis also induces arteriolar
      vasodilation which plays a major role in initiating the decrease in arterial blood volume.
      Therefore, administration of a vasoconstrictor may decrease paracentesis induced arteriolar
      vasodilation and prevent the resulting decrease in effective arterial blood volume. Two
      randomised pilot studies suggest that Terlipressin may be as effective as intravenous albumin
      in preventing a decrease in effective arterial blood volume in patients with cirrhosis
      treated by paracentesis for tense ascites. The combined treatment, albumin plus terlipressin,
      could have additional effect and may improve ascites in such patients. In several studies the
      combined therapy, albumin plus terlipressin, has shown beneficial effect in cirrhotic
      patients with hepatorenal syndrome characterized by a sever decrease in arterial blood volume
      and vasodilation. In these studies, combined therapy was well tolerated.The aim of this study
      is to compare ascites relapse between two groups of cirrhotic patients with recidivation
      ascites treated by paracentesis and intravenous albumin perfusion plus terlipressin or
      placebo. In this double blind randomized multi-center trial, all patients receive albumin
      perfusion at the dose 8 g/l of removed ascites and Terlipressin (1mg) or placebo,
      administrated before and at the end of the paracentesis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean number of paracentesis between the 2 groups over a 6 months period</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total ascites retrieval</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cirrhosis complications groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver transplantation and deaths</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terlipressin safety</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of days of hospitalization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay between inclusion and the first rehospitalisation for ascites retrieval</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Terlipressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.</description>
    <arm_group_label>Terlipressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 18 years old and more with cirrhosis and refractory ascites define by the
             international ascites club.

          -  Vital status non engaged in the 2 months

        Exclusion Criteria:

          -  cardiovascular disease : previous or actual angina pectoralis, myocardial infarction,
             heart failure, rhythm or conduction disorders, repolarisation abnormality on ECG

          -  respiratory disease: previous or actual chronic pulmonary insufficiency, asthma

          -  uncontrolled hypertension

          -  acute portal vein thrombosis (less then 3 months) or currently treated.

          -  chronic renal insufficiency (creatin &gt; 15 mg/L)

          -  severe hepatic encephalopathy

          -  Alcoholic hepatitis or gastrointestinal bleeding in the last 3 months

          -  hepatocellular carcinoma

          -  severe illness with life threatening

          -  pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Carbonell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Antoine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CARBONELL Nicolas</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology. 1998 Jan;27(1):264-72. Review.</citation>
    <PMID>9425946</PMID>
  </reference>
  <reference>
    <citation>Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987 Jan-Feb;7(1):122-8.</citation>
    <PMID>3804191</PMID>
  </reference>
  <reference>
    <citation>Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, Porayko M, Moreau R, Garcia-Tsao G, Jimenez W, Planas R, Arroyo V. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003 Jul;38(1):258-66. Review.</citation>
    <PMID>12830009</PMID>
  </reference>
  <reference>
    <citation>Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Domènech E, Abecasis R, Angeli P, Ruiz-Del-Arbol L, Planas R, Solà R, Ginès P, Terg R, Inglada L, Vaqué P, Salerno F, Vargas V, Clemente G, Quer JC, Jiménez W, Arroyo V, Rodés J. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996 Oct;111(4):1002-10.</citation>
    <PMID>8831595</PMID>
  </reference>
  <reference>
    <citation>Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997 Aug;113(2):579-86.</citation>
    <PMID>9247479</PMID>
  </reference>
  <reference>
    <citation>Ginès P, Titó L, Arroyo V, Planas R, Panés J, Viver J, Torres M, Humbert P, Rimola A, Llach J, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988 Jun;94(6):1493-502.</citation>
    <PMID>3360270</PMID>
  </reference>
  <reference>
    <citation>Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology. 2006 Mar;43(3):385-94. Review.</citation>
    <PMID>16496352</PMID>
  </reference>
  <reference>
    <citation>Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, Dadamessi I, Silvain C, Bonny C, Oberti F, Gournay J, Lebrec D, Grouin JM, Guémas E, Golly D, Padrazzi B, Tellier Z. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int. 2006 Feb;26(1):46-54.</citation>
    <PMID>16420509</PMID>
  </reference>
  <reference>
    <citation>Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, Poynard T, Binn M, Grangé JD, Valla D, Lebrec D. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut. 2002 Jan;50(1):90-4.</citation>
    <PMID>11772973</PMID>
  </reference>
  <reference>
    <citation>Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):303-7.</citation>
    <PMID>16460491</PMID>
  </reference>
  <reference>
    <citation>Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003 Feb;18(2):152-6.</citation>
    <PMID>12542598</PMID>
  </reference>
  <reference>
    <citation>Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002 Oct;36(4 Pt 1):941-8.</citation>
    <PMID>12297842</PMID>
  </reference>
  <reference>
    <citation>Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002 Apr;122(4):923-30.</citation>
    <PMID>11910344</PMID>
  </reference>
  <reference>
    <citation>Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol. 2002 Feb;14(2):153-8.</citation>
    <PMID>11981339</PMID>
  </reference>
  <reference>
    <citation>Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000 Jul;33(1):43-8.</citation>
    <PMID>10905585</PMID>
  </reference>
  <reference>
    <citation>Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, Le Moine O. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg. 2001 Jan-Mar;64(1):15-9.</citation>
    <PMID>11322061</PMID>
  </reference>
  <reference>
    <citation>Singh V, Kumar B, Nain CK, Singh B, Sharma N, Bhalla A, Sharma AK. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med. 2006 Jul;260(1):62-8.</citation>
    <PMID>16789980</PMID>
  </reference>
  <reference>
    <citation>Appenrodt B, Wolf A, Grünhage F, Trebicka J, Schepke M, Rabe C, Lammert F, Sauerbruch T, Heller J. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int. 2008 Aug;28(7):1019-25. doi: 10.1111/j.1478-3231.2008.01734.x. Epub 2008 Apr 11.</citation>
    <PMID>18410283</PMID>
  </reference>
  <reference>
    <citation>Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008 May;134(5):1360-8. doi: 10.1053/j.gastro.2008.02.014. Epub 2008 Feb 13.</citation>
    <PMID>18471513</PMID>
  </reference>
  <reference>
    <citation>Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008 May;134(5):1352-9. doi: 10.1053/j.gastro.2008.02.024. Epub 2008 Feb 14.</citation>
    <PMID>18471512</PMID>
  </reference>
  <reference>
    <citation>Gadano A, Moreau R, Vachiery F, Soupison T, Yang S, Cailmail S, Sogni P, Hadengue A, Durand F, Valla D, Lebrec D. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol. 1997 Jun;26(6):1229-34.</citation>
    <PMID>9210608</PMID>
  </reference>
  <reference>
    <citation>Valla D, Lee SS, Moreau R, Hadengue A, Sayegh R, Lebrec D. [Effects of glypressin on the splanchnic and systemic circulation in patients with cirrhosis]. Gastroenterol Clin Biol. 1985 Dec;9(12):877-80. French.</citation>
    <PMID>3830801</PMID>
  </reference>
  <reference>
    <citation>Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996 Jan;23(1):164-76. Review.</citation>
    <PMID>8550036</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>June 12, 2015</last_update_submitted>
  <last_update_submitted_qc>June 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory ascites</keyword>
  <keyword>Cirrhosis Terlipressin</keyword>
  <keyword>Paracentesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

